[Secondary effects of the treatment of hypermicrofilaremic loiasis using ivermectin].

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Bulletin de la Société de Pathologie Exotique

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Environmental Science

• Identifiers
  PMID 8555762
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy of ivermectin treatment of Loa loa filariasis patients without microfilaraemias.

  1994cited by this paper
• Reduction of microfilaraemia with single high-dose of ivermectin in loiasis.

  1993cited by this paper
• Tolerance and efficacy of single high-dose ivermectin for the treatment of loiasis.

  1993cited by this paper
• Ivermectin treatment of loiasis.

  1992cited by this paper
• [Value of ivermectin in the initial treatment of loaiasis].

  1991cited by this paper
• Five cases of encephalitis during treatment of loiasis with diethylcarbamazine.

  1991cited by this paper
• [Therapeutic trial with ivermectin in loiasis with medium and high microfilaremia].

  1991cited by this paper
• [Loa loa filariasis, encephalitis and treatment with Notézine: an underestimated complication?].

  1989cited by this paper
• Ivermectin in loiasis and concomitant O. volvulus and M. perstans infections.

  1988cited by this paper
• Avermectin B1 toxicity in a herd of Murray Grey cattle.

  1987cited by this paper
• [Current problems of loaiasis].

  1978cited by this paper

• Revisiting the Loa loa microfilaremia thresholds above which serious adverse events may occur with ivermectin treatment

  2025cites this paper
• Safety and Short-term Efficacy of a Single Dose of 2 mg Moxidectin in Loa loa–Infected Individuals: A Double-Blind, Randomized Ivermectin-Controlled Trial With Ascending Microfilarial Densities

  2024cites this paper
• Inflammation and hemostasis in loiasis before and after ivermectin treatment: A biological pilot cross-sectional study

  2024cites this paper
• A novel antigen biomarker for detection of high-level of Loa loa microfilaremia

  2024cites this paper
• Inflammation and fibrinolysis in loiasis before and after ivermectin treatment: a biological pilot cross-sectional study

  2024cites this paper
• The African eye worm: current understanding of the epidemiology, clinical disease, and treatment of loiasis.

  2023cites this paper
• Historical overview and geographical distribution of neglected tropical diseases amenable to preventive chemotherapy in the Republic of the Congo: A systematic review

  2022cites this paper
• Onchocerciasis drug development: from preclinical models to humans

  2021cites this paper
• Advances in Preclinical Platforms of Loa loa for Filarial Neglected Tropical Disease Drug and Diagnostics Research

  2021cites this paper
• Implications for annual retesting after a test-and-not-treat strategy for onchocerciasis elimination in areas co-endemic with Loa loa infection: an observational cohort study

  2020cites this paper
• Massive microfilaremia in a dog subclinically infected with Acanthocheilonema dracunculoides.

  2020cites this paper
• Une loase oculaire: à propos d’un cas

  2020cites this paper
• Effect of a Single Standard Dose (150–200 μg/kg) of Ivermectin on Loa loa Microfilaremia: Systematic Review and Meta-analysis

  2019cites this paper
• Analysis of severe adverse effects following community-based ivermectin treatment in the Democratic Republic of Congo

  2019cites this paper
• Mouse models of Loa loa

  2019cites this paper
• Implementation of test-and-treat with doxycycline and temephos ground larviciding as alternative strategies for accelerating onchocerciasis elimination in an area of loiasis co-endemicity: the COUNTDOWN consortium multi-disciplinary study protocol

  2019cites this paper
• Impact of repeated annual community directed treatment with ivermectin on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa

  2018cites this paper
• Potential Role for Flubendazole in Limiting Filariasis Transmission: Observations of Microfilarial Sensitivity.

  2018cites this paper
• Loa loa infection detection using biomarkers: current perspectives

  2018cites this paper
• Interactions filaire/poumon dans le modèle murin de filariose Litosomoides sigmodontis

  2017cites this paper
• Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection

  2017cites this paper
• Ivermectin treatment of Loa loa hyper-microfilaraemic baboons (Papio anubis): Assessment of microfilarial load reduction, haematological and biochemical parameters and histopathological changes following treatment

  2017cites this paper
• [Subconjunctival loiasis: A case report].

  2016cites this paper
• Structural and Functional Analyses of Secretory and Excretory Proteins from Onchocerca volvulus as Basis for Rational Drug Design

  2016cites this paper
• Effect of Two or Six Doses 800 mg of Albendazole Every Two Months on Loa loa Microfilaraemia: A Double Blind, Randomized, Placebo-Controlled Trial

  2016cites this paper
• Parasitological, Hematological and Biochemical Characteristics of a Model of Hyper-microfilariaemic Loiasis (Loa loa) in the Baboon (Papio anubis)

  2015cites this paper
• Repurposed Automated Handheld Counter as a Point-of-Care Tool to Identify Individuals ‘At Risk’ of Serious Post-Ivermectin Encephalopathy

  2014cites this paper
• CAMEROON ACADEMY OF SCIENCES ACADEMIE DES SCIENCES DU CAMEROUN CAMEROON ACADEMY OF SCIENCES RECENT ADVANCES IN ONCHOCERCIASIS RESEARCH AND IMPLICATIONS FOR CONTROL PRODUCED BY AN EXPERT COMMITTEE OF THE CAMEROON ACADEMY OF SCIENCES

  2013cites this paper
• Wolbachia endosymbiont of Onchocerca volvulus: driver of immunopathology and target for therapy

  2012cites this paper
• Integrated rapid mapping of onchocerciasis and loiasis in the Democratic Republic of Congo: impact on control strategies.

  2011cites this paper
• ntegrated rapid mapping of onchocerciasis and loiasis in the Democratic epublic of Congo : Impact on control strategies fework

  2011cites this paper
• A Senegalese man with gross hematuria

  2010cites this paper
• Current Evidence on the Use of Antifilarial Agents in the Management of Bancroftian Filariasis

  2010cites this paper
• The case / a Senegalese man with gross hematuria.

  2009cites this paper
• Loa loa microfilarial periodicity in ivermectin-treated patients: comparison between those developing and those free of serious adverse events.

  2009cites this paper
• Operational lessons from 20 years of the Mectizan Donation Program for the control of onchocerciasis

  2008cites this paper
• [Management of blood eosinophilia in an outpatient clinic for tropical diseases].

  2007cites this paper
• Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose (approximately 25 microg/kg) versus current standard dose (150 microg/kg).

  2007cites this paper
• Onchocerciasis-related epilepsy? Prospects at a time of uncertainty.

  2006cites this paper
• The Mectizan® Donation Program – highlights from 2005

  2006cites this paper
• Loiasis

  2006cites this paper
• [Systemic adverse reactions with ivermectin treatment of scabies].

  2006cites this paper
• First case of ivermectin-induced severe hepatitis.

  2006cites this paper
• A possible case of spontaneous Loa loa encephalopathy associated with a glomerulopathy

  2006cites this paper
• [Ivermectin].

  2004cites this paper
• Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen.

  2004cites this paper
• Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon

  2003cites this paper
• Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future

  2003cites this paper
• A Framework for Decision-Making for Mass Distribution of Mectizan® in Areas Endemic for Loa loa

  2003cites this paper
• Serious adverse events following treatment with ivermectin for onchocerciasis control: a review of reported cases

  2003cites this paper
• Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.

  2003cites this paper
• Identification and specificity of a 38 kDa Loa loa antigenic fraction in sera from high-microfilaraemic Gabonese patients

  2003cites this paper
• Effects of a 3-day regimen of albendazole (800 mg daily) on Loa loa microfilaraemia

  2002cites this paper
• A case of loiasis in Rome

  2002cites this paper
• [Hyperendemic loaiasis in the Tikar plain, shrub savanna region of Cameroon].

  2001cites this paper
• Chemotherapy for patients with multiple parasitic infections

  2001cites this paper
• Cellular responses to Loa loa experimental infection in mandrills (Mandrillus sphinx) vaccinated with irradiated infective larvae

  2000cites this paper
• Human onchocerciasis: the essential partnership between research and disease control efforts

  2000cites this paper
• Analysis of renal function in onchocerciasis patients before and after therapy.

  1999cites this paper
• Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis.

  1998cites this paper
• Challenges for the future: loiasis.

  1998cites this paper
• [Diagnosis and management of parasitic hypereosinophilia].

  1998cites this paper
• [Release of Loa loa antigens after treatment with ivermectin].

  1998cites this paper
• [Nephropathy and filariasis from Loa loa. Apropos of 1 case of adverse reaction to a dose of ivermectin].

  1997cites this paper
• Anthelmintics

  1997cites this paper
• [Study of the distribution of human filariasis in West Province of Cameroon].

  1997cites this paper
• Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection.

  1997cites this paper
• Decreased prevalence and intensity of Loa loa infection in a community treated with ivermectin every three months for two years.

  1996cites this paper
• Splenectomy for suspected malignant lymphoma in two patients with loiasis.

  1996cites this paper
• Severe adverse reaction risks during mass treatment with ivermectin in loiasis-endemic areas.

  1996cites this paper
• Immunologic Aspects of the Pathogenesis of Human Onchocerciasis

  year unknowncites this paper